Regeneron
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Regeneron and other ETFs, options, and stocks.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
REGN News
Oppenheimer analyst Hartaj Singh raised the firm’s price target on Regeneron to $1,175 from $1,125 and keeps an Outperform rating on the shares ahead of the Q1...
Loading... Loading... Thursday, AbbVie Inc ABBV released topline results from LEVEL UP, an open-label, efficacy assessor-blinded head-to-head Phase 3b/4 study...
AbbVie (NYSE:ABBV) said a head-to-head study showed its drug Rinvoq was more effective in treating certain symptoms of moderate-to-severe atopic dermatitis than...
Analyst ratings
69%
of 29 ratingsMore REGN News
Regeneron (REGN) is expected to deliver flat earnings compared to the year-ago quarter on higher revenues when it reports results for the quarter ended March 20...
(Adds study details in paragraphs 2-3, background in paragraphs 4-5) April 25 (Reuters) - AbbVie said on Thursday its drug, Rinvoq, for treating a type of infl...
For Immediate Release Chicago, IL – April 25, 2024 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research a...
Regeneron Pharmaceuticals (NASDAQ:REGN) and Mammoth Biosciences will collaborate on in vivo CRISPR-based gene editing therapies for several tissues and cell typ...
Regeneron Pharmaceuticals and Mammoth Biosciences announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies f...
April 25 (Reuters) - Regeneron Pharmaceuticals and Mammoth Biosciences will collaborate to research, develop and commercialize gene editing therapies for multip...
RerF/iStock via Getty Images Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported Q1 2024 results that showed strong sequential and year-over-year net sales growth o...
